SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating REGENXBIO Inc. for Potential Breaches of Fiduciary Duty By Its Board of DirectorsPRNewsWire • 09/14/20
REGENXBIO Announces Dosing of First Patient in Phase II AAVIATE™ Trial of RGX-314 for the Treatment of Wet AMD Using Suprachoroidal DeliveryPRNewsWire • 09/09/20
REGENXBIO Announces FDA Clearance of IND for Phase II Trial of RGX-314 for the Treatment of Diabetic Retinopathy Using Suprachoroidal DeliveryPRNewsWire • 08/25/20
REGENXBIO's (RGNX) CEO Ken Mills on Q2 2020 Results - Earnings Call TranscriptSeeking Alpha • 08/07/20
REGENXBIO Reports Second Quarter 2020 Financial Results and Operational HighlightsPRNewsWire • 08/06/20
REGENXBIO Announces Additional Positive Interim Phase I/IIa Trial Update and Program Updates for RGX-314 for the Treatment of Wet AMDPRNewsWire • 08/04/20
REGENXBIO To Host Conference Call on August 6 to Discuss Second Quarter 2020 Financial Results and Recent Operational HighlightsPRNewsWire • 07/30/20
Analysts Estimate Regenxbio (RGNX) to Report a Decline in Earnings: What to Look Out forZacks Investment Research • 07/29/20
REGENXBIO Provides Update on Progress of Clinical Programs for Rare Genetic Neurodegenerative DiseasesPRNewsWire • 07/08/20
REGENXBIO, Inc. (RGNX) CEO Kenneth Mills on Q1 2020 Results - Earnings Call TranscriptSeeking Alpha • 05/08/20
Regenxbio (RGNX) May Report Negative Earnings: Know the Trend Ahead of Q1 ReleaseZacks Investment Research • 04/28/20
Regenxbio Is A Leader In Gene Therapies - A Case Where The Platform Is Worth More Than The PipelineSeeking Alpha • 04/24/20
REGENXBIO, Inc. (RGNX) CEO Kenneth Mills on Q4 2019 Results - Earnings Call TranscriptSeeking Alpha • 02/27/20
Earnings Preview: Regenxbio (RGNX) Q4 Earnings Expected to DeclineZacks Investment Research • 02/19/20
Regenxbio: Fairly Valued Given The Current Risks But Could Have Eye-Watering UpsideSeeking Alpha • 12/10/19
This Biotech Dived After The FDA Put Its Gene Therapy Study On PauseInvestors Business Daily • 11/06/19
REGENXBIO, Inc. (RGNX) CEO Kenneth Mills on Q3 2019 Results - Earnings Call TranscriptSeeking Alpha • 11/06/19